Rapid Response to Infectious Disease Transmission Requires Real-Time Data Solutions

Rapid Response to Infectious Disease Transmission Requires Real-time Data Solutions

For infectious disease studies of any kind, the ability to accelerate trial timelines, while also providing high-quality data and reducing barriers to patient participation, is highly prized. When the World Health Organization (WHO) declares a virus a pandemic, there’s no time to lose. Infectious disease drug developers must respond immediately to find treatment and prophylactic candidates, and rapidly move them through the drug development process.

Uninterrupted Real-time Data Continuity

The COVID-19 vaccines are an example of what can happen when the government and industry work together to fight infectious diseases. As SARS-CoV-2 spread across the world, researchers raced to develop effective vaccines, diagnostics, and treatments. Timelines that usually took up to 10 years were condensed to less than twelve months, and the FDA granted Emergency Use Authorization in record time.

Drug development during COVID-19 showed us how digital technology solutions can help clinical trials stay on track during times of extreme disruption. Videoconferencing, mobile technology, and remote monitoring allow patients to participate in infectious disease research projects from anywhere. At the same time, access to real-time data in the form of advanced direct data capture (DDC), electronic patient-reported outcomes (ePRO), and electronic clinical outcomes assessments (eCOA) provide infectious study teams with immediate insights and interim analysis reporting.

When conducting infectious disease research, speed and infection prevention are important. DDC, ePRO, and eCOA all help sponsors generate the real-time data they need — with less face-to-face interaction.

Benefits of Clinical ink platform in the Clinical Trial Experience

  • Real-time access to direct data capture (DDC), eCOA, and ePRO data enables immediate insights and interim analysis reporting.
  • Near elimination of source data verification (SDV) enables remote source data review and vastly reduces on-site monitoring.
  • Supports decentralized trials — whether your infectious disease research project takes place in mobile units, an ambulatory center, remote medical tents, or somewhere else entirely.
  • Central monitoring allows for quicker oversight and faster response to patient needs when their health status changes, and when in-person visits aren’t possible, patients still have a way to participate. If a pandemic requires clinical trials to scale back or eliminate in-person everything, sponsors can use DDC to enter and remotely monitor data.
  • Applications work on- or offline so you can collect data under changing environments, and you have the ability to collect multiple forms within a patient’s chart across different tablets.
  • Infectious disease studies often require heightened attention to infection prevention as well as equipment that can function in non-traditional settings. Easily sterilized tablets and styluses with glove-compatible data entry, enhance safety for patients and clinicians.
  • Rapid deployment means you can start your study sooner.

In evolving infectious disease situations, the ability to respond rapidly to individual or epidemiologic developments is of primary importance. No matter where your study takes place, you need the support and guarantee of proven digital technology solutions.

Scroll to Top